Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome

Neurobiology of Disease

Khaleel A. Razak¹  Jonathan W. Lovelace²  Carrie R. Jonak³  Iryna M. Ethell³  Devin K. Binder⁴ 

[1]Neuroscience Graduate Program, University of California, Riverside, United States of America

[2]Department of Psychology, University of California, Riverside, United States of America

[3]Division of Biomedical Sciences, School of Medicine, University of California, Riverside, United States of America

[4]Neuroscience Graduate Program, University of California, Riverside, United States of America

关键词: Fragile X syndrome;    Autism;    Auditory cortex;    Sensory hypersensitivity;    EEG;    Multielectrode array;   

DOI  :  

来源: DOAJ

【 摘 要 】

Fragile X Syndrome (FXS) is a leading known genetic cause of intellectual disability with symptoms that include increased anxiety and social and sensory processing deficits. Recent EEG studies in humans with FXS have identified neural oscillation deficits that include increased resting state gamma power, increased amplitude of auditory evoked potentials, and reduced inter-trial phase coherence of sound-evoked gamma oscillations. Identification of comparable EEG biomarkers in mouse models of FXS could facilitate the pre-clinical to clinical therapeutic pipeline. However, while human EEG studies have involved 128-channel scalp EEG acquisition, no mouse studies have been performed with more than three EEG channels. In the current study, we employed a recently developed 30-channel mouse multielectrode array (MEA) system to record and analyze resting and stimulus-evoked EEG signals in WT vs. Fmr1 KO mice. Using this system, we now report robust MEA-derived phenotypes including higher resting EEG power, altered event-related potentials (ERPs) and reduced inter-trial phase coherence to auditory chirp stimuli in Fmr1 KO mice that are remarkably similar to those reported in humans with FXS. We propose that the MEA system can be used for: (i) derivation of higher-level EEG parameters; (ii) EEG biomarkers for drug testing; and (ii) mechanistic studies of FXS pathophysiology.

【 授权许可】

Unknown